Winds of change in CRPC blow new course for Teva/OncoGenix's custirsen
This article was originally published in Scrip
Executive Summary
Teva and OncoGenix are making changes to the Phase III programme for their novel prostate cancer drug custirsen that may delay its arrival, but will hopefully allow it to enter the market better armed against its competitors.